Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma

Pancreatology

Volumn 6, Issue 6, 2006, Pages 635-641

  Bang, Seungmin ^a   Jeon, Tae Joo ^a   Kim, Myoung Hwan ^a   Park, Jeong Youp ^a   Park, Seung Woo ^a   Chung, Jae Bock ^a   Song, Si Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; Pancreatic cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; GEMCITABINE; ONDANSETRON;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPENIC FEVER; NNEUTROPENIC FEVER; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 33847636709     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000097784     Document Type: Article

References (22)

1. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996;78(suppl 3):580-591.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
4. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-4422.
5. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-6117.
6. Carmichael J, Fink U, Russell RC, et al: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-105.
7. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
8. Okada S, Sakata Y, Matsuno S, et al: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999;80:438-443.
9. Androulakis N, Kourousis C, Dimopoulos MA, et al: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999;17:1779-1785.
10. Ryan DP, Kulke MH, Fuchs CS, et al: A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002;94:97-103.
11. Louvet C, Andre T, Lledo G, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512-1518.
12. Oettle H, Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002;95(suppl 4):912-922.
13. Hidalgo M, Castellano D, Paz-Ares L, et al: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-592.
14. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-530.
15. Van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ: Scheduling of gemcitabine and cisplatin in Lewis lung tumour-bearing mice. Eur J Cancer 1999;35:808-814.
16. Abratt RP, Sandler A, Crino L, et al: Combined cisplatin and gemcitabine for nonsmall cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol 1998;25(suppl 9):35-43.
17. Shepherd FA, Abratt R, Crino L, et al: The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer 2000;30:117-125.
18. World Health Organization: Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979.
19. Philip PA, Zalupski MM, Vaitkevicius VK, et al: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92:569-577.
20. Heinemann V, Wilke H, Mergenthaler HG, et al: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000;11:1399-1403.
21. Cascinu S, Labianca R, Catalano V, et al: Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2003;14:205-208.
22. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-910.